Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ASCEND-8: safety data of ceritinib with or without food in NSCLC

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 26.10.18
Views: 1541

Prof Byoung Chul Cho - Yonsei Cancer Center, Seoul, Republic of Korea

Prof Byoung Chul Cho speaks with ecancer at ESMO 2018 in Munich about results of the ASCEND-8 study which investigated the primary efficacy and updated safety of ceritinib (450 mg or 600 mg) with food vs 750 mg fasted in ALK positive metastatic NSCLC.

Prof Cho explains that ASCEND-8 was designed to look at the drawback of using ceritinib to treat NSCLC as, although it shows excellent progression-free survival, it does cause Gi toxicity.

He goes on to say that the study demonstrated that 450mg of ceritinib with meal and 750mg fasted had a similar pharmacokinetic profile.

ecancer's filming has been kindly supported by MSD through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Related videos

follow us

SIOG e-learning July 2017

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation